Publications by authors named "Marwa Houssein"
Growth or death? Control of cell destiny by mTOR and autophagy pathways.
Prog Biophys Mol Biol
December 2023
Article Synopsis
- - mTOR (mammalian target of rapamycin) is a key regulator of cell growth and metabolism, existing in two complexes: mTORC1, which responds to nutrient availability and is inhibited by rapamycin, and mTORC2, which is not activated by dietary conditions.
- - mTORC1 and mTORC2 play vital roles in processes such as protein synthesis, gene regulation, and apoptosis, as well as autophagy, which helps recycle damaged molecules during nutrient scarcity.
- - The mTOR pathway is often activated in tumors, and its dysregulation is linked to diseases like cancer. Using mTOR inhibitors to control autophagy presents a possible treatment strategy.
DPPA4 is essential for the pluripotent stem cell state, yet its function is poorly understood. DPPA4 is localized in the nucleus, where it is associated with active chromatin. We now report that it is also present in the cytosol, where it appears as diffused clouds, distinct foci and sometimes as spaghetti-like structures.
View Article and Find Full Text PDFOver the past decades, the rapid pace of vaccine development saved 37 million lives, mostly children. The ongoing corona virus disease (COVID-19) pandemic caused the death of more than 4 million worldwide. During 2020, to encounter the pandemic, scientists developed more than 300 vaccines projects against SARS-CoV (severe acute respiratory syndrome coronavirus 2).
View Article and Find Full Text PDFBackground: Gallotannin (GT) is a polyphenol that possesses interesting anticancer properties. However, the mechanisms underlying its antitumor effects have not been well defined.
Objective: This study was designed to clarify the mechanisms underlying GT antitumor effects in colon cancer cell lines.
Human T cell lymphotropic virus-1 (HTLV-1) is the causative agent of adult T cell leukemia (ATL), an aggressive malignancy of mature activated T cells. Although many therapeutic strategies are available, none are effective and most patients experience recurrence of the disease. Over the past decade, many drugs have been discovered that showed promising therapeutic potential against ATL but which remain in the preclinical testing phase.
View Article and Find Full Text PDFAims: To reduce the dose of arsenic used against human T-cell leukemia/lymphoma and to sensitize cells to drug treatment, we combined arsenic/interferon-alpha (As/IFN-α) with thymoquinone (TQ) in HTLV-I positive (HuT-102 and C91) and HTLV-1 negative (CEM and Jurkat) cell lines.
Main Methods: Cells were treated with TQ, As/IFN-α and combinations. Trypan blue and flow cytometry were used to investigate viability and cell cycle effects.